Cornerstone Pharmaceutical-B(02616.HK): The application for the approval of the registration of the new drug Puxihua (Pirapinib capsules) transferred from overseas to domestic production has been approved by the National Medical Products Administration.

Zhixin Finance APP news, Cornerstone Pharma-B (02616.HK) announced that the application for the listing of its RET inhibitor Pralsetinib Capsules (100mg) has been approved by the China National Medical Products Administration (NMPA) after the drug was transferred from overseas to domestic production. It is expected that starting from 2026, the supply of this product in the Chinese mainland market will gradually transition from imported products to domestically produced products.